+39 02 610346.1 - info@newron.com

J. Donald de Bethizy

J. Donald de Bethizy

Donald deBethizy, PhD, brings more than 20 years of experience in managing and financing life science related technologies, and has played a key role in building and advising several life science companies. In his role as President, CEO and Director on the Board of Manager of Santaris Pharma A/S he led the sale of the company to Roche; he co-founded Targacept, Inc. and served as its President and CEO for 15 years. Donald led Targacept’s private and public financings totaling approximately $330 million including the company’s Initial Public Offering (IPO) in April, 2006.He played a key role in developing business relationships with GSK, AstraZeneca, Aventis, and Dr. Falk Pharma which generated non-dilutive revenues of over $300 million. At present, he is President of Innovent LLC and White City Consulting ApS as well as Director on the Board of Noxxon Pharma AG and ArGEN-X NV (Netherlands) and Chairman of the boards of Albumedix A/S and Rigontec GmbH . Donald is Chairman of the Company' Research and Development Committee. Donald is a US citizen and resident of Denmark.